We connect technology and healthcare professionals

AI-Powered radiotherapy planning

TheraPanacea’s zero-click AI automation platform for high-precision radiotherapy is in clinical use in 150+ departments in Europe and world-wide with up to +90% time saving for dosimetrists, RTTs and radiation oncologists. TheraPanacea offers AI powered workflow modules for automatic segmentation of OARs and selected targets for CT and MR, decision support for adaptive therapy and advanced fusion capabilities.

AI automated workflows

ART-Plan™ is a web-browser based, scalable and modular AI automation platform for radiotherapy.  Current modules include:

Annotate™: AI-powered software that provides fully automatic delineation of 200+ CT and MRI-based organs at risk (OARs) and lymph nodes from Simulator-to-TPS within 2-3 minutes and with comparable accuracy as clinical experts, utilizing latest consensus contouring guidelines.

MR-Box™: Generates MRI-based pseudo-CT (conventional MRIs and MR linacs) for MR-only and MR guided radiotherapy to avoid registration errors, cost saving and improved patient comfort. Compatible with Annotate for auto-contouring of OARs & lymph nodes on MRI scans.

SmartFuse™: The first AI-powered software for high-precision rigid and elastic fusion, that includes the management of 4D-CT and a real-time deformation of contours for faster replanning.

AdaptBox™ : Provides decision making support using customisable objective metrics for adaptive radiotherapy by utilizing AI to generate an enhanced and augmented pseudo-CT from CBCT with a CT-like FOV, expert like contours using AI auto-contouring as well as re-calculating and comparing dose metrics to the active treatment plan.

Clinical Evidence
https://www.therapanacea.eu/resources/publications/

TheraPanacea logo

About TheraPanacea

TheraPanacea is a serial award-winning medical technology company founded in 2017 harnessing AI to develop cutting-edge software for more efficient and precise cancer care. Their radiotherapy AI automation platform ART-Plan™ has been CE-marked in 2019 (FDA clearance, etc. followed soon) and since then ART-Plan is already in use across Europe and the US.

  • In use in over 150 radiotherapy departments across Europe and world-wide.
  • 1 out of 4 radiotherapy patients in France is being auto-contoured with TheraPanacea’s ART-Plan.
  • 150,000 patient cases are being auto-contoured per year with ART-Plan world-wide.

Get in contact

Frederik Baastrup Hammer

Frederik Baastrup Hammer

Founder & Partner

+45 60 14 18 84

fba@humanbytes.ai

Ulrik Juul Rokkedal Therkildsen

Ulrik Juul Rokkedal Therkildsen

CEO & Partner

+45 21 38 70 02

urt@humanbytes.ai

Martin Frandsen

Martin Frandsen

Nordic Customer Success Manager

+45 22 21 52 75

mf@humanbytes.ai

Anders Bille

Anders Bille

Nordic Sales Manager

+45 22 98 21 38

ab@humanbytes.ai